|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/11/16 Actinium Pharmaceuticals, Inc. 10-K 12/31/15 64:5.6M Edgar Agents LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 937K
2: EX-10.56 Third Amendment to the 2013 Amended and Restated HTML 21K
Stock Plan, Effective as of December 22, 2015
3: EX-10.57 Office Space License Agreement, Dated March 19, HTML 73K
2016, by and Between Actinium Pharmaceuticals,
Inc. and Relmada Therapeutics, Inc.
4: EX-21.1 List of Subsidiaries HTML 16K
5: EX-23.1 Consent of Gbh CPAs, Pc. HTML 18K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 23K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 22K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 18K
9: EX-32.2 Certification -- §906 - SOA'02 HTML 18K
16: R1 Document and Entity Information HTML 47K
17: R2 Consolidated Balance Sheets HTML 80K
18: R3 Consolidated Balance Sheets (Parenthetical) HTML 39K
19: R4 Consolidated Statements of Operations HTML 55K
20: R5 Consolidated Statement of Changes in Stockholders' HTML 64K
Equity (Deficit)
21: R6 Consolidated Statements of Cash Flows HTML 95K
22: R7 Description of Business and Summary of Significant HTML 71K
Accounting Policies
23: R8 Related Party Transactions HTML 45K
24: R9 Prepaid Expenses and Other Current Assets HTML 30K
25: R10 Property and Equipment HTML 33K
26: R11 Note Payable HTML 26K
27: R12 Derivatives HTML 52K
28: R13 Commitments and Contingencies HTML 58K
29: R14 Equity HTML 140K
30: R15 Income Taxes HTML 59K
31: R16 Subsequent Events HTML 29K
32: R17 Description of Business and Summary of Significant HTML 100K
Accounting Policies (Policies)
33: R18 Description of Business and Summary of Significant HTML 36K
Accounting Policies (Tables)
34: R19 Related Party Transactions (Tables) HTML 22K
35: R20 Prepaid Expenses and Other Current Assets (Tables) HTML 28K
36: R21 Property and Equipment (Tables) HTML 25K
37: R22 Derivatives (Tables) HTML 50K
38: R23 Commitments and Contingencies (Tables) HTML 26K
39: R24 Equity (Tables) HTML 74K
40: R25 Income Taxes (Tables) HTML 53K
41: R26 Description of Business and Summary of Significant HTML 30K
Accounting Policies (Details)
42: R27 Description of Business and Summary of Significant HTML 28K
Accounting Policies (Details 1)
43: R28 Description of Business and Summary of Significant HTML 42K
Accounting Policies (Details Textual)
44: R29 Related Party Transactions (Details) HTML 25K
45: R30 Related Party Transactions (Details Textual) HTML 91K
46: R31 Prepaid Expenses and Other Current Assets HTML 29K
(Details)
47: R32 Property and Equipment (Details) HTML 33K
48: R33 Property and Equipment (Details Textual) HTML 23K
49: R34 Note Payable (Details) HTML 33K
50: R35 Derivatives (Details) HTML 30K
51: R36 Derivatives (Details 1) HTML 38K
52: R37 Derivatives (Details Textual) HTML 32K
53: R38 Commitments and Contingencies (Details) HTML 34K
54: R39 Commitments and Contingencies (Details 1) HTML 21K
55: R40 Commitments and Contingencies (Details Textual) HTML 114K
56: R41 Equity (Details) HTML 76K
57: R42 Equity (Details Textual) HTML 275K
58: R43 Income Taxes (Details) HTML 26K
59: R44 Income Taxes (Details 1) HTML 55K
60: R45 Income Taxes (Details Textual) HTML 26K
61: R46 Subsequent Events (Details) HTML 47K
63: XML IDEA XML File -- Filing Summary XML 106K
62: EXCEL IDEA Workbook of Financial Reports XLSX 62K
10: EX-101.INS XBRL Instance -- atnm-20151231 XML 1.32M
12: EX-101.CAL XBRL Calculations -- atnm-20151231_cal XML 83K
13: EX-101.DEF XBRL Definitions -- atnm-20151231_def XML 476K
14: EX-101.LAB XBRL Labels -- atnm-20151231_lab XML 1.17M
15: EX-101.PRE XBRL Presentations -- atnm-20151231_pre XML 750K
11: EX-101.SCH XBRL Schema -- atnm-20151231 XSD 179K
64: ZIP XBRL Zipped Folder -- 0001213900-16-011534-xbrl Zip 125K
Exhibit 10.56
THIRD AMENDMENT
TO
ACTINIUM PHARMACEUTICALS, INC. 2013 AMENDED AND RESTATED STOCK PLAN
Pursuant to Section 14 of the 2013 Amended and Restated Stock Plan, as amended (the “Plan”) of Actinium Pharmaceuticals, Inc. (the “Company”), the Board of Directors of the Company has duly adopted a resolution, conditioned upon approval by the stockholders of the Company, approving this Third Amendment to the Plan to increase the total number of shares of common stock, par value $.001 per share, of the Company (the “Common Stock”) reserved and available for issuance under the Plan as follows:
1. Section 3 of the Plan is hereby amended to read in its entirety as follows:
“Subject to the provisions of Section 14 of the Plan, the maximum aggregate number of Shares reserved for issuance to Participants under the Plan is 9,250,000, and the maximum aggregate number of Shares that may be granted in the form of Incentive Stock Options is 9,250,000. The Shares may be authorized, but unissued, or reacquired Common Stock. If an award should expire or become unexercisable for any reason without having been exercised in full, the unpurchased Shares that were subject thereto shall, unless the Plan shall have been terminated, become available for future grant under the Plan. In addition, any Shares of Common Stock which are retained by the Company upon exercise of an award in order to satisfy the exercise or purchase price for such award or any withholding taxes due with respect to such exercise or purchase shall be treated as not issued and shall continue to be available under the Plan. Shares issued under the Plan and later repurchased by the Company pursuant to any repurchase right which the Company may have shall not be available for future grant under the Plan.”
2. All other terms and provisions of the Plan shall remain unchanged and in full force and effect as written.
3. A majority in voting interest of the stockholders present in person or by proxy and entitled to vote at the meeting of stockholders at which this Third Amendment N was considered, has duly approved this Third Amendment to the Plan.
IN WITNESS WHEREOF, this Amendment No. 3 to the Plan is made effective this 22nd day of December, 2015.
| ACTINIUM PHARMACEUTICALS, INC. | ||
| By: | /s/ Kaushik J. Dave | |
| Name: | Kaushik J. Dave | |
| Title: | Chief Executive Officer | |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/29/24 Actinium Pharmaceuticals, Inc. 10-K 12/31/23 65:17M EdgarAgents LLC/FA 3/31/23 Actinium Pharmaceuticals, Inc. 10-K 12/31/22 60:8.1M EdgarAgents LLC/FA 3/25/22 Actinium Pharmaceuticals, Inc. 10-K 12/31/21 56:4.2M EdgarAgents LLC/FA 3/31/21 Actinium Pharmaceuticals, Inc. 10-K 12/31/20 56:3.5M EdgarAgents LLC/FA |